Rheumatoid Arthritis Drugs Market: Industry Analysis and forecast 2026: By Drug Type, Distribution Channel and Region

Rheumatoid Arthritis Drugs Market: Industry Analysis and forecast 2026: By Drug Type, Distribution Channel and Region

Market Scenario

Rheumatoid Arthritis Drugs Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. Rheumatoid Arthritis Drugs Market Drivers and Restrains: Rheumatoid arthritis (RA) is an autoimmune disorder that causes pain and inflammation in the joints. Rheumatoid arthritis disease mostly affects the joints along with articular tissues and extra articular organs such as hands, wrists, elbows, knees, and ankles. The rheumatoid arthritis also disturbs the cardiac and respiratory system. It is known as a systemic disease. It commonly affects almost XX% of the geriatric population. It mostly onsets during middle age, and women are affected XX times as frequently as men. As there is no permanent cure for RA, the goals of the treatment are to decrease pain, reduce inflammation, prevent bone deformity, and improve a person’s whole body function. Several therapeutics and medication have been developed to relieve and treat the symptoms of rheumatoid arthritis in recent years. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The rheumatoid arthritis drugs market has driven by factors, which are rise in incidences of rheumatoid arthritis and upsurge in geriatric population. Additionally, transition from symptom management to slowing the progression of the disease further impells the market growth. However, side effects associated with the medication and higher cost of biologics & biosimilars are restraining the market growth at global level. The developments in the field of biosimilars and novel biologics are expected to offer lucrative opportunities for the growth of the RA drugs market. Demand for development of newer and biotechnologically enhanced products such as biologics and biosimilar is rising worldwide, owing to the treatment efficiency of drugs. Hence, major players operating in the rheumatoid arthritis drugs market are financing in research and development programs in order to develop novel drugs. Rise in investment in research and development programs by key players of the market is expected to boost the market significantly during the forecast period. Rheumatoid Arthritis Drugs Market Segmentation Analysis: Based on the drug type, the rheumatoid arthritis drugs market has been segmented into Disease-modifying anti-rheumatic drugs (DMARDs), Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and Biologic response modifiers (biologics). In term of revenue, the biologics segment held the dominant market share in 2018, owing to the considerably high cost of these medicine and the wide usage of drugs in severe rheumatoid disease. Biotechnological research and developments in rheumatoid arthritis drugs are likely to increase the biologic drugs segment growth in the near future. NSAIDs are mostly used for the symptomatic treatment of rheumatic disorders. DMARDs are considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Based on the distribution channel, the rheumatoid arthritis drugs market has been segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy. The hospital pharmacy segment is projected to grow at the largest CAGR of XX% during the forecast period, owing to the increase in number of hospitals and rise in preference of the geriatric patient population to undergo treatment at hospitals. Rheumatoid Arthritis Drugs Market Regional Analysis: Geographically, the rheumatoid arthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the rheumatoid arthritis drugs market in 2018 owing to the high rate of adoption of biologic drugs and high health care expenditure in the region. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period due to Increase in the incidences of rheumatoid arthritis disease and increasing health care expenditure in the region. Moreover, low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to Asia Pacific from across the world. Developed countries witnessed high rates of aging as compared to the developing countries. This is attributed to improved health care infrastructure, reimbursement policies, and advancement in health care facilities in these countries A report covers the recent development for the rheumatoid arthritis drugs market like Takeda Pharmaceuticals financed US$ XX Bn in research and development activities. According to a yearly report published by GlaxoSmithKline plc, the company partnered with more than 1,500 companies and other academic organizations across the world for the development of novel drugs. Rheumatoid Arthritis Drugs Market Competitive landscape Major Key players operating in this market are AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer, Inc. Manufacturers in the rheumatoid arthritis drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of rheumatoid arthritis drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding rheumatoid arthritis drugs market dynamics, structure by analyzing the market segments, and project the rheumatoid arthritis drugs market size. Clear representation of competitive analysis of key players by drug type, price, financial position, product portfolio, growth strategies, and regional presence in the rheumatoid arthritis drugs market make the report investor’s guide.

Scope of the Rheumatoid Arthritis Drugs Market:

Rheumatoid Arthritis Drugs Market, Drug type:

• Disease-modifying anti-rheumatic drugs (DMARDs) • Non-steroidal anti-inflammatory drugs (NSAIDs) • Corticosteroids • Biologic response modifiers (biologics)

Rheumatoid Arthritis Drugs Market, by Distribution Channel:

• Hospital Pharmacy • Retail Pharmacy • Online Pharmacy

Rheumatoid Arthritis Drugs Market, by Region:

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Rheumatoid Arthritis Drugs Market, Major Players:

• AbbVie Inc. • Boehringer Ingelheim GmbH • Novartis AG • Regeneron Pharmaceuticals, Inc. • Pfizer, Inc. • Johnson & Johnsons Services, Inc • Bristol-Myers Squibb Company • F. Hoffmann-La Roche Ltd. • Celegene Corporations • MedImmune, LLC • Takeda Pharmaceutical Company Ltd. • Biogen Inc. • Celltrion Inc. • Janssen Biotech, Inc. • Amgen, Inc. • Eli Lily and company • Merck & Co. Inc

Table of Contents

Rheumatoid Arthritis Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Rheumatoid Arthritis Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast 6.1. Global Rheumatoid Arthritis Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Drug Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 7.4. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Drug Type 7.5. Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type 7.6. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type 8. Global Rheumatoid Arthritis Drugs Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 8.4. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Distribution Channel 8.5. Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel 8.6. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel 9. Global Rheumatoid Arthritis Drugs Market Analysis, by Region 9.1. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region 9.2. Global Rheumatoid Arthritis Drugs Market Size (US$ Bn) Forecast, by Region 9.3. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region 10. North America Rheumatoid Arthritis Drugs Market Analysis 10.1. Key Findings 10.2. North America Rheumatoid Arthritis Drugs Market Overview 10.3. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 10.4. North America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 10.4.1. Hospital Pharmacy 10.4.2. Retail Pharmacy 10.4.3. Online Pharmacy 10.5. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 10.6. North America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 10.6.1. Disease-modifying anti-rheumatic drugs (DMARDs) 10.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 10.6.3. Corticosteroids 10.6.4. Biologic response modifiers (biologics) 10.7. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country 10.8. North America Rheumatoid Arthritis Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Rheumatoid Arthritis Drugs Market Analysis, by Country 10.10. U.S. Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 10.10.1. Hospital Pharmacy 10.10.2. Retail Pharmacy 10.10.3. Online Pharmacy 10.11. U.S. Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 10.11.1. Disease-modifying anti-rheumatic drugs (DMARDs) 10.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 10.11.3. Corticosteroids 10.11.4. Biologic response modifiers (biologics) 10.12. Canada Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 10.12.1. Hospital Pharmacy 10.12.2. Retail Pharmacy 10.12.3. Online Pharmacy 10.13. Canada Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 10.13.1. Disease-modifying anti-rheumatic drugs (DMARDs) 10.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 10.13.3. Corticosteroids 10.13.4. Biologic response modifiers (biologics) 10.14. North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis 10.14.1. By Drug Type 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Rheumatoid Arthritis Drugs Market Analysis 11.1. Key Findings 11.2. Europe Rheumatoid Arthritis Drugs Market Overview 11.3. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 11.4. Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.4.1. Hospital Pharmacy 11.4.2. Retail Pharmacy 11.4.3. Online Pharmacy 11.5. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 11.6. Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.6.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.6.3. Corticosteroids 11.6.4. Biologic response modifiers (biologics) 11.7. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country 11.8. Europe Rheumatoid Arthritis Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Rheumatoid Arthritis Drugs Market Analysis, by Country 11.10. Germany Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.10.1. Hospital Pharmacy 11.10.2. Retail Pharmacy 11.10.3. Online Pharmacy 11.11. Germany Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.11.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.11.3. Corticosteroids 11.11.4. Biologic response modifiers (biologics) 11.12. U.K. Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.12.1. Hospital Pharmacy 11.12.2. Retail Pharmacy 11.12.3. Online Pharmacy 11.13. U.K. Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.13.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.13.3. Corticosteroids 11.13.4. Biologic response modifiers (biologics) 11.14. France Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.14.1. Hospital Pharmacy 11.14.2. Retail Pharmacy 11.14.3. Online Pharmacy 11.15. France Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.15.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.15.3. Corticosteroids 11.15.4. Biologic response modifiers (biologics) 11.16. Italy Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.16.1. Hospital Pharmacy 11.16.2. Retail Pharmacy 11.16.3. Online Pharmacy 11.17. Italy Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.17.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.17.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.17.3. Corticosteroids 11.17.4. Biologic response modifiers (biologics) 11.18. Spain Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.18.1. Hospital Pharmacy 11.18.2. Retail Pharmacy 11.18.3. Online Pharmacy 11.19. Spain Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.19.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.19.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.19.3. Corticosteroids 11.19.4. Biologic response modifiers (biologics) 11.20. Rest of Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 11.20.1. Hospital Pharmacy 11.20.2. Retail Pharmacy 11.20.3. Online Pharmacy 11.21. Rest of Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 11.21.1. Disease-modifying anti-rheumatic drugs (DMARDs) 11.21.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 11.21.3. Corticosteroids 11.21.4. Biologic response modifiers (biologics) 11.22. Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis 11.22.1. By Drug Type 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Rheumatoid Arthritis Drugs Market Overview 12.3. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 12.4. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.4.1. Hospital Pharmacy 12.4.2. Retail Pharmacy 12.4.3. Online Pharmacy 12.5. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.6.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.6.3. Corticosteroids 12.6.4. Biologic response modifiers (biologics) 12.7. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis, by Country 12.10. China Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.10.1. Hospital Pharmacy 12.10.2. Retail Pharmacy 12.10.3. Online Pharmacy 12.11. China Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.11.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.11.3. Corticosteroids 12.11.4. Biologic response modifiers (biologics) 12.12. India Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.12.1. Hospital Pharmacy 12.12.2. Retail Pharmacy 12.12.3. Online Pharmacy 12.13. India Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.13.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.13.3. Corticosteroids 12.13.4. Biologic response modifiers (biologics) 12.14. Japan Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.14.1. Hospital Pharmacy 12.14.2. Retail Pharmacy 12.14.3. Online Pharmacy 12.15. Japan Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.15.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.15.3. Corticosteroids 12.15.4. Biologic response modifiers (biologics) 12.16. ASEAN Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.16.1. Hospital Pharmacy 12.16.2. Retail Pharmacy 12.16.3. Online Pharmacy 12.17. ASEAN Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.17.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.17.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.17.3. Corticosteroids 12.17.4. Biologic response modifiers (biologics) 12.18. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 12.18.1. Hospital Pharmacy 12.18.2. Retail Pharmacy 12.18.3. Online Pharmacy 12.19. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 12.19.1. Disease-modifying anti-rheumatic drugs (DMARDs) 12.19.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 12.19.3. Corticosteroids 12.19.4. Biologic response modifiers (biologics) 12.20. Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis 12.20.1. By Drug Type 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Overview 13.3. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 13.4.1. Hospital Pharmacy 13.4.2. Retail Pharmacy 13.4.3. Online Pharmacy 13.5. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 13.6.1. Disease-modifying anti-rheumatic drugs (DMARDs) 13.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 13.6.3. Corticosteroids 13.6.4. Biologic response modifiers (biologics) 13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis, by Country 13.10. GCC Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 13.10.1. Hospital Pharmacy 13.10.2. Retail Pharmacy 13.10.3. Online Pharmacy 13.11. GCC Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 13.11.1. Disease-modifying anti-rheumatic drugs (DMARDs) 13.11.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 13.11.3. Corticosteroids 13.11.4. Biologic response modifiers (biologics) 13.12. South Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 13.12.1. Hospital Pharmacy 13.12.2. Retail Pharmacy 13.12.3. Online Pharmacy 13.13. South Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 13.13.1. Disease-modifying anti-rheumatic drugs (DMARDs) 13.13.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 13.13.3. Corticosteroids 13.13.4. Biologic response modifiers (biologics) 13.14. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 13.14.1. Hospital Pharmacy 13.14.2. Retail Pharmacy 13.14.3. Online Pharmacy 13.15. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 13.15.1. Disease-modifying anti-rheumatic drugs (DMARDs) 13.15.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 13.15.3. Corticosteroids 13.15.4. Biologic response modifiers (biologics) 13.16. Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis 13.16.1. By Drug Type 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Rheumatoid Arthritis Drugs Market Analysis 14.1. Key Findings 14.2. South America Rheumatoid Arthritis Drugs Market Overview 14.3. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type 14.4. South America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 14.4.1. Hospital Pharmacy 14.4.2. Retail Pharmacy 14.4.3. Online Pharmacy 14.5. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel 14.6. South America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 14.6.1. Disease-modifying anti-rheumatic drugs (DMARDs) 14.6.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 14.6.3. Corticosteroids 14.6.4. Biologic response modifiers (biologics) 14.7. South America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country 14.8. South America Rheumatoid Arthritis Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 14.9.1. Hospital Pharmacy 14.9.2. Retail Pharmacy 14.9.3. Online Pharmacy 14.10. Brazil Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 14.10.1. Disease-modifying anti-rheumatic drugs (DMARDs) 14.10.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 14.10.3. Corticosteroids 14.10.4. Biologic response modifiers (biologics) 14.11. Mexico Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 14.11.1. Hospital Pharmacy 14.11.2. Retail Pharmacy 14.11.3. Online Pharmacy 14.12. Mexico Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 14.12.1. Disease-modifying anti-rheumatic drugs (DMARDs) 14.12.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 14.12.3. Corticosteroids 14.12.4. Biologic response modifiers (biologics) 14.13. Rest of South America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type 14.13.1. Hospital Pharmacy 14.13.2. Retail Pharmacy 14.13.3. Online Pharmacy 14.14. Rest of South America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel 14.14.1. Disease-modifying anti-rheumatic drugs (DMARDs) 14.14.2. Non-steroidal anti-inflammatory drugs (NSAIDs) 14.14.3. Corticosteroids 14.14.4. Biologic response modifiers (biologics) 14.15. South America Rheumatoid Arthritis Drugs Market Attractiveness Analysis 14.15.1. By Drug Type 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. AbbVie Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Boehringer Ingelheim GmbH 15.3.3. Novartis AG 15.3.4. Regeneron Pharmaceuticals, Inc. 15.3.5. Pfizer, Inc. 15.3.6. Johnson & Johnsons Services, Inc 15.3.7. Bristol-Myers Squibb Company 15.3.8. F. Hoffmann-La Roche Ltd. 15.3.9. Celegene Corporations 15.3.10. MedImmune, LLC 15.3.11. Takeda Pharmaceutical Company Ltd. 15.3.12. Biogen Inc. 15.3.13. Celltrion Inc. 15.3.14. Janssen Biotech, Inc. 15.3.15. Amgen, Inc. 15.3.16. Eli Lily and company 15.3.17. Merck & Co. Inc. 16. Primary Key Insights

About This Report

Report ID38331
Category Healthcare
Published DateNov 2019
No of Pages192
Contact Us